Diabetic Ketoacidosis Treatment Guidelines

Initial Assessment and Management

• The American Diabetes Association recommends performing laboratory evaluation including plasma glucose, blood urea nitrogen/creatinine, serum ketones, electrolytes, osmolality, urinalysis, urine ketones, arterial blood gases, complete blood count, and electrocardiogram for patients with diabetic ketoacidosis (DKA) 1
• Obtain bacterial cultures of urine, blood, and throat if infection is suspected and administer appropriate antibiotics for patients with DKA 1
• Chest X-ray should be obtained if clinically indicated for patients with DKA 1

Fluid Resuscitation and Electrolyte Management

• The American Diabetes Association recommends beginning with isotonic saline at a rate of 15-20 ml/kg body weight/hour for the first hour of treatment for DKA 1, 2
• Total fluid replacement should be approximately 1.5 times the 24-hour maintenance requirements for patients with DKA 2
• Include 20-30 mEq/L potassium in the infusion once renal function is assured for patients with DKA 1, 2
• Monitor serum potassium closely as insulin therapy lowers serum potassium levels for patients with DKA 2

Insulin Therapy

• The American Diabetes Association recommends continuous intravenous regular insulin infusion as the preferred treatment method for moderate to severe DKA 2, 3
• Start with an IV bolus of regular insulin at 0.1 units/kg followed by continuous infusion at 0.1 units/kg/hour for patients with DKA 2, 3

Monitoring and Transition to Subcutaneous Insulin

• Check blood glucose every 2-4 hours and measure serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH every 2-4 hours for patients with DKA 2, 3
• When DKA resolves and the patient can eat, start a multiple-dose insulin schedule using a combination of short/rapid-acting and intermediate/long-acting insulin 2, 3
• Administer basal insulin 2-4 hours before stopping the IV insulin infusion for patients with DKA 4

Manejo de Cetoacidosis Diabética con Insulina Subcutánea

Protocolo de Dosificación de Insulina Subcutánea

• La dosis de ajuste de insulina debe reducirse a 0,05-0,1 U/kg/hora hasta la resolución completa de la cetoacidosis (pH ≥7,3, bicarbonato ≥18 mEq/L), según la guía de la Diabetes Care 5

Monitorización Durante el Tratamiento

• La glucemia debe verificarse cada 2-4 horas mientras el paciente esté en ayuno, según la guía de la Diabetes Care 5

Insulin Regimen After DKA Resolution

Timing of Transition

• Administer basal insulin (glargine or detemir) 2-4 hours BEFORE stopping the IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as recommended by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Monitoring Requirements

• Continue monitoring electrolytes, particularly potassium, as insulin drives potassium intracellularly, according to the American Association of Clinical Endocrinologists, with a strength of evidence based on clinical guidelines 6

Critical Pitfalls to Avoid

• Do not stop IV insulin without prior basal insulin administration—this is the most common error leading to DKA recurrence, as warned by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Discharge Planning

• Structured discharge planning should begin at admission and include patient education on insulin administration, glucose monitoring, and sick day management, as recommended by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Management of Insulin Infusion in DKA with Severe Hypokalemia

Critical Threshold for Insulin Initiation

• The American Diabetes Association recommends delaying insulin infusion until serum potassium is ≥3.3 mEq/L to prevent life-threatening cardiac arrhythmias and death 7
• Do not start insulin if potassium is <3.3 mEq/L, as this is the absolute cutoff established by the American Diabetes Association guidelines 7

Initial Management Algorithm

• Begin isotonic saline at 15-20 ml/kg/hour for the first hour while holding insulin, as recommended by the American Diabetes Association 7
• Once renal function is confirmed, add 20-40 mEq/L potassium to IV fluids, using a combination of 2/3 KCl or potassium-acetate and 1/3 KPO4 7
• Obtain electrocardiogram to assess for cardiac effects of hypokalemia, as recommended by the American Diabetes Association 7
• Continue aggressive potassium repletion until K+ ≥3.3 mEq/L, as recommended by the American Diabetes Association 7

Initiation of Insulin Therapy

• Once K+ ≥3.3 mEq/L, start IV bolus of regular insulin at 0.1 units/kg, followed by continuous infusion at 0.1 units/kg/hour, as recommended by the American Diabetes Association 7
• Target glucose decline of 50-75 mg/dl/hour, as recommended by the American Diabetes Association 7

Insulin Drip Protocol for Diabetic Ketoacidosis

Initial Insulin Dosing Protocol

• The American Diabetes Association recommends giving an IV bolus of 0.1 units/kg regular insulin for adults with moderate-severe DKA, with a strength of evidence based on high-quality trials 8
• The American Diabetes Association suggests starting a continuous infusion of 0.1 units/kg/hour regular insulin for adults with moderate-severe DKA, with a moderate strength of evidence based on clinical experience 9, 8
• The target glucose decline is 50-75 mg/dL per hour, according to the American Diabetes Association, with a moderate strength of evidence based on clinical experience 8

Adjusting the Insulin Infusion

• The American Diabetes Association recommends verifying adequate hydration status if glucose does not fall by 50 mg/dL in the first hour, with a low strength of evidence based on expert opinion 8
• The American Diabetes Association suggests doubling the insulin infusion rate every hour until achieving a steady decline of 50-75 mg/dL/hour, with a moderate strength of evidence based on clinical experience 8

Concurrent Fluid and Electrolyte Management

• The American Diabetes Association recommends using 2/3 KCl or potassium-acetate and 1/3 KPO4 for potassium replacement, with a moderate strength of evidence based on clinical experience 9, 8

Monitoring Requirements

• The American Diabetes Association suggests checking venous pH every 2-4 hours, with a moderate strength of evidence based on clinical experience 9, 8
• The American Diabetes Association recommends direct measurement of β-hydroxybutyrate in blood for ketone monitoring, with a high strength of evidence based on high-quality trials 9

DKA Resolution Criteria

• The American Diabetes Association states that all of the following must be met for DKA resolution: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L, with a moderate strength of evidence based on clinical experience 9

Transition to Subcutaneous Insulin

• The American Diabetes Association recommends continuing IV insulin for 1-2 hours after subcutaneous insulin is given, with a moderate strength of evidence based on clinical experience 9

Alternative Approach for Mild-Moderate Uncomplicated DKA

• The American Diabetes Association suggests that subcutaneous rapid-acting insulin analogs combined with aggressive fluid management can be as effective and more cost-effective than IV insulin for hemodynamically stable, alert patients with mild-moderate DKA, with a moderate strength of evidence based on clinical experience 10, 11

Initiating Subcutaneous Insulin in Diabetic Ketoacidosis

Transition Criteria

• The American Diabetes Association recommends initiating subcutaneous insulin when diabetic ketoacidosis (DKA) has completely resolved (pH ≥7.3, bicarbonate ≥18 mEq/L, glucose <200 mg/dL, anion gap ≤12 mEq/L) and the patient can tolerate oral intake, administering it 2-4 hours before discontinuing intravenous insulin infusion to prevent DKA recurrence 12
• The American Diabetes Association suggests that the transition from intravenous to subcutaneous insulin requires all of the following criteria to be met simultaneously: pH venous >7.3, bicarbonate serum ≥18 mEq/L, glucose <200 mg/dL, anion gap ≤12 mEq/L, and patient's ability to tolerate oral intake, with the patient being hemodynamically stable 12

Transition Protocol

• The American Diabetes Association recommends administering long-acting basal insulin (glargine or detemir) subcutaneously 2-4 hours before discontinuing intravenous insulin infusion to allow for absorption and prevent DKA recurrence 12
• The American Diabetes Association suggests initiating a multiple-dose regimen with a combination of short-acting/rapid insulin and intermediate-acting/long-acting insulin once the resolution criteria are met, and continuing intravenous infusion for 1-2 hours after administering subcutaneous insulin 12
• The American Diabetes Association recommends monitoring glucose levels every 2-4 hours during the transition period 12

Alternative Approach for Mild to Moderate Uncomplicated DKA

• For hemodynamically stable patients with mild to moderate DKA, subcutaneous insulin with rapid-acting analogs combined with aggressive fluid management may be as effective as intravenous insulin and more cost-effective, according to the American Diabetes Association 12
• This approach requires the patient to be hemodynamically stable and alert, have mild to moderate DKA, receive adequate fluid replacement, and have frequent monitoring of capillary glucose levels 12

Monitoring During Transition

• The American Diabetes Association recommends monitoring glucose levels every 2-4 hours during the transition period 12

Common Pitfalls to Avoid

• The American Diabetes Association advises against discontinuing intravenous insulin without prior administration of subcutaneous basal insulin, as this is a common error that leads to DKA recurrence 12
• The American Diabetes Association recommends against initiating subcutaneous insulin before complete resolution of metabolic acidosis 12
• The American Diabetes Association suggests avoiding premature transition when the patient is still unable to tolerate oral intake 12

Insulin Infusion Discontinuation Criteria and Overlap Protocol in DKA

Basal Insulin Overlap Timing

• Administer a long‑acting basal insulin (e.g., glargine or detemir) subcutaneously 2–4 hours before stopping the intravenous insulin infusion to ensure continuous insulin coverage and prevent rebound hyperglycemia or recurrent DKA. This recommendation is endorsed by the American Diabetes Association guidelines. 13

• Maintaining the intravenous insulin infusion for 1–2 hours after the basal insulin injection allows adequate absorption of the subcutaneous dose and further reduces the risk of a coverage gap that can precipitate ketoacidosis. (Guideline‑based practice) 13

Monitoring Parameters Prior to Discontinuation

• Prior to stopping the insulin infusion, check the following metabolic parameters every 2–4 hours until they remain stable:

Guideline Recommendations for Fluid Management, Electrolyte Replacement, Monitoring, and Insulin Transition in Adult Diabetic Ketoacidosis

Fluid Resuscitation

Potassium Replacement

Laboratory Monitoring

Transition to Subcutaneous Insulin

Subcutaneous Insulin Dose Calculation (Simplified Method)

Alternative Subcutaneous Management for Mild‑Moderate, Uncomplicated DKA

Insulin Infusion and Management of Diabetic Ketoacidosis

Insulin Selection and Standard Dosing

• The American Diabetes Association (ADA) recommends using only regular (short‑acting) insulin for intravenous infusion; rapid‑acting analogs must not be administered intravenously. 17
• For moderate‑to‑severe DKA, the ADA protocol calls for an initial IV bolus of regular insulin 0.1 U/kg given as a direct push, followed by a continuous infusion of 0.1 U/kg/h via an IV pump. 17
• Insulin should be prepared by adding 100 U regular insulin to 100 mL normal saline, yielding a concentration of 1 U/mL. 17

Alternative Low‑Dose Protocol (Pediatrics or Mild DKA)

• The Pediatric Society guideline (Pediatrics, 2008) suggests a low‑dose regimen without a bolus: start a continuous infusion of regular insulin at 0.05 U/kg/h; this may lower the risk of hypokalemia, particularly in malnourished children. 18

Fluid and Electrolyte Management

• Begin isotonic saline at 15–20 mL/kg/h for the first hour, administered concurrently with the insulin infusion. 17
• Once serum potassium is ≥3.3 mEq/L and urine output is adequate, add 20–30 mEq/L potassium to each liter of replacement fluid. 17
• Maintain serum potassium between 4–5 mEq/L throughout DKA treatment. 17

Glucose Control and Dextrose Addition

• When plasma glucose falls to 250 mg/dL, switch the IV fluid to D5W combined with 0.45–0.75 % NaCl while continuing the insulin infusion at the same rate. 17
• Target a glucose range of 150–200 mg/dL until full resolution of ketoacidosis. 17
• In euglycemic DKA (initial glucose < 250 mg/dL), start D5W together with normal saline from the outset of insulin therapy. 17

Monitoring Frequency

• The ADA advises checking blood glucose, serum electrolytes (especially potassium), venous pH, serum bicarbonate, anion gap, BUN, creatinine, and osmolality every 2–4 hours until the patient is stable. 17

Transition to Subcutaneous Insulin

• Administer a long‑acting basal insulin (glargine or detemir) subcutaneously 2–4 hours before stopping the IV insulin infusion. 17
• Continue the IV insulin infusion for an additional 1–2 hours after the basal dose to ensure adequate absorption. 17
• The basal dose should be approximately 50 % of the total 24‑hour IV insulin amount, given as a single daily injection; the remaining 50 % is divided equally among three meals as rapid‑acting prandial insulin. 17

Alternative Subcutaneous‑Only Approach for Mild‑Moderate DKA

• For hemodynamically stable, alert patients with mild‑moderate DKA, the ADA notes that subcutaneous rapid‑acting insulin analogs (0.1–0.2 U/kg every 1–2 hours) combined with aggressive IV fluid replacement can be as effective and more cost‑effective than continuous IV insulin. 17

Safety Checks and Common Pitfalls (ADA Recommendations)

• Potassium prerequisite: Do not initiate insulin if serum potassium is <3.3 mEq/L; replete potassium first. 17
• Glucose‑driven insulin hold: Never hold insulin when glucose falls; instead add dextrose to the IV fluid while maintaining insulin infusion to clear ketones. 17
• Overlap before discontinuation: Never stop IV insulin abruptly; overlap with subcutaneous basal insulin for 2–4 hours to prevent DKA recurrence. 17
• Ketone monitoring: Do not rely solely on urine ketones; they lag behind serum ketone clearance and do not measure β‑hydroxybutyrate. 17
• Underdosing in severe DKA: If acidosis persists despite adequate hydration, increase insulin to 4–6 U/h (or higher) while providing appropriate glucose supplementation. 17